Sitamaquine as a putative antileishmanial drug candidate: From the mechanism of action to the risk of drug resistance

Parasite

Volumn 18, Issue 2, 2011, Pages 115-119

  Loiseau, P M ^a   Cojean, S ^a   Schrevel J ^b  

^a UNIVERSITÉ PARIS SUD   (France)

^b MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

Aminoquinoline; Drug action; Leishmaniasis; Sitamaquine

Indexed keywords

LEISHMANIA DONOVANI;

8 AMINOQUINOLINE; 8-AMINOQUINOLINE; AMINOQUINOLINE DERIVATIVE; ANTIPROTOZOAL AGENT;

ANIMAL; BIOAVAILABILITY; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; HUMAN; LEISHMANIA; ORAL DRUG ADMINISTRATION; REVIEW; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; AMINOQUINOLINES; ANIMALS; ANTIPROTOZOAL AGENTS; BIOLOGICAL AVAILABILITY; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; HUMANS; LEISHMANIA; LEISHMANIASIS, VISCERAL;

EID: 80052050504     PISSN: 1252607X     EISSN: 17761042     Source Type: Journal    
DOI: 10.1051/parasite/2011182115     Document Type: Review

References (29)

1. BERMAN J.D. & LEE L.S. Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. American Journal of Tropical Medicine and Hygiene, 1983, 32, 753-759. (Pubitemid 13041002)
2. BEVERIDGE E., GOODWIN L.G. & WALLS L.P. A new series of leishmanicides. Nature, 1958, 182, 316-317.
3. BORIES C., COJEAN S., HUTEAU F. & LOISEAU P.M. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomedicine and Pharmacotherapy, 2008, 62, 164-167. (Pubitemid 351381937)
4. COÏMBRA E.S., LIBONG D., COJEAN S., SAINT-PIERRE-CHAZALET M., SOLGADI A., LE MOYEC L., DUENAS-ROMERO A.M., CHAMINADE P. & LOISEAU P.M. Mechanism of interaction of sitamaquine with Leishmania donovani. The Journal of Antimicrobial Chemotherapy, 2010, 65, 2548-2555.
5. DESJEUX P. Leishmaniasis: current situation and new perspectives. Comparative Immunology, Microbiology and Infectious Diseases, 2004, 27, 305-318. (Pubitemid 38842803)
6. DIETZE R., CARVALHO S.F.G., VALLI L.C., BERMAN J., BREWER T., MILHOUS W., SANCHEZ J., SCHUSTER B. & GROGL M. Phase II trial of WR6026, an orally administrated 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. American Journal of Tropical Medicine and Hygiene, 2001, 65, 685-689. (Pubitemid 34049456)
7. DUEÑAS-ROMERO A.M., LOISEAU P.M. & SAINT-PIERRE-CHAZALET M. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochimica et Biophysica Acta, 2007, 1768, 246-252. (Pubitemid 46138097)
8. ELDERFIELD R.C., MERTEL H.E., MITCH R.T., WEMPEN I.M. & WERBLE E.J. Synthesis of primaquine and certain of its analogs. Journal of the American Chemical Society, 1955, 77, 4816-4819.
9. GARNIER T., BROWN M.B., LAWRENCE M.J. & CROFT S.L. In vitro and in vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. Journal of Pharmacy and Pharmacology, 2006, 58, 1043-1054. (Pubitemid 44213636)
10. JHA T.K., SUNDAR S., THAKUR C.P., BACHMANN P., KARBWANG J., FISCHER C., VOSS A. & BERMAN J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine, 1999, 341, 1795-800.
11. JHA T.K., SUNDAR S., THAKUR C.P., FELTON J.M., SABIN A.J. & HORTON J. A phase II dose-ranging study of sitamaquine for treatment of visceral leishmaniasis in India. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1005-1011. (Pubitemid 43038244)
12. KINNAMON K.E., STECK E.A., LOIZEAUX P.S., HANSON W.L., CHAPMAN W.L. JR. & WAITS V.B. The antileishmanial activity of lepidines. American Journal of Tropical Medicine and Hygiene, 1978, 27, 751-757. (Pubitemid 8398077)
13. LANGRETH S.G., BERMAN J.D., RIORDAN G.P. & LEE L.S. Finestructure alterations in Leishmania tropica within macrophages exposed to antileishmanial drugs in vitro. Journal of Protozoology, 1983, 30, 555-561. (Pubitemid 14232617)
14. LÓPEZ-MARTÍN C., PÉREZ-VICTORIA J.M., CARVALHO L., CASTANYS S. & GAMARRO F. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrobial Agents and Chemotherapy, 2008, 52, 4030-4036.
15. MUSCHIOL C., BERGER M.R., SCHULER B., SCHERF H.R., GARZON F.T., ZELLER W.J., UNGER C., EIBL H.J. & SCHMÄHL D. Alkyl phosphocholines: toxicity and anticancer properties. Lipids, 1987, 22, 930-934. (Pubitemid 18001400)
16. SHERWOOD J.A., GACHIHI G.S., MUIGAI R.K., SKILLMAN D.R., MUGO M., RASHID J.R., WASUNNA K.M., WERE J.B., KASILI S.K., MBUGUA J.M. ET AL. Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clinical Infectious Diseases, 1994, 19, 1034-1039. (Pubitemid 24380014)
17. SINDERMANN H. & ENGEL J. Development of miltefosine as an oral treatment for leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100 (Suppl 1), S17-S20. (Pubitemid 44490164)
18. SOTO J., ARANA B.A., TOLEDO J., RIZZO N., VEGA J.C., DIAZ A., LUZ M., GUTIERREZ P., ARBOLEDA M., BERMAN J.D., JUNGE K., ENGEL J. & SINDERMANN H. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases, 2004, 38, 1266-1272. (Pubitemid 38608569)
19. SOTO J. & BERMAN J. Treatment of New World cutaneous leishmaniasis with miltefosine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100 (Suppl 1), S34-S40. (Pubitemid 44490170)
20. SOTO J. & TOLEDO J.T. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infectious Diseases, 2007, 7, 7. (Pubitemid 44917777)
21. SUNDAR S., JHA T.K., THAKUR C.P., ENGEL J., SINDERMANN H., FISCHER C., JUNGE K., BRYCESON A. & BERMAN J. Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine, 2002, 347, 1739-1746. (Pubitemid 35375612)
22. SUNDAR S., RAI M., CHAKRAVARTY J., AGARWAL D., AGRAWAL N., VAILLANT M., OLLIARO P., MURRAY H.W. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clinical Infectious Diseases, 2008, 47, 1000-1006.
23. THEOHARIDES A.D., CHUNG H., VELAZQUEZ H. Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes. Biochemical Pharmacology, 1985, 34, 181-188. (Pubitemid 15153409)
24. THEOHARIDES A.D., KIM M.M., ASHMORE R.W. & SHIPLEY L.A. Identification and quantification of human urinary metabolites of a candidate 8-aminoquinoline antileishmanial drug WR-6026. Proceedings of American Society of Experimental Biology, 1987, 46, 865.
25. 2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochemical Journal, 1992, 284, 463-467.
26. VERCESI A., RODRIGUES C., CASTISTI R. & DOCAMPO R. Presence of a Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs. FEBS Letters, 2000, 473, 203-206. (Pubitemid 30254291)
27. WASUNNA M.K., RHASHID J.R., MBUI J., KIRIGI G., KINOTI D., LODENYO H., FELTON J.M., SABIN A.J. & HORTON J. A phase II dose-increasing study of sitamaquine for treatment of visceral leishmaniasis in Kenya. American Journal of Tropical Medicine and Hygiene, 2005, 73, 871-876. (Pubitemid 41688461)
28. WORLD HEALTH ORGANIZATION. Leishmaniasis Disease Burden. Available from: http://www.who.int/leishmaniasis, 2010.
29. YEATES C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Current Opinion in Investigational Drugs, 2002, 3, 1446-1452.